LEMAITRE VASCULAR, INC (NASDAQ: LMAT) NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited)

For the year and/d December 31, 2019 \$ 21, 183 Operating income as reported inspect of restructuring income (source) 1.39 1.39 Adjuited Queue 12, 1000 \$ 22, 444 Port is year inclusioning income (source) \$ 21, 75 Adjuited Queue 12, 1000 \$ 20, 755 Adjuited Increase 1, 0, 1018 \$ 21, 700 Rescription in an explorition on the year ended December 31, 2019 \$ 20, 755 Rescription in an explorition on the year ended December 31, 2019 \$ 50, 670 Comparing expense as reported \$ 51, 720 \$ Adjusted inperating expenses \$ 51, 720 \$ 53, 204 Adjusted increase in operating expenses \$ 51, 720 \$ 53, 204 Adjusted increase in operating expenses \$ 51, 720 \$ 53, 204 Adjusted increase exclusing expenses \$ 51, 720 \$ 53, 204 Adjusted increase exclusing expenses \$ 51, 720 \$ 53, 204 Adjusted increase exclusing expenses \$ 51, 720 \$ 52, 224 Adjusted increase exclusing expenses	Reconciliation between GAAP and Non-GAAP operating income excluding impact of st	trong dollar:				
Impact of existracting integrating138Impact of existracting integrating1.22Adjusted operating increme28,200Corporating increme as reported28,200Adjusted operating increme for the year ended December 31, 20193Adjusted operating encome5Adjusted operating encome5Adjusted operating encome5Statistical increase in operating expenses: For the year ended December 31, 20195Statistical increase in operating expenses: For the year ended December 31, 20195Statistical increase in operating expenses3For the year ended December 31, 20185Corporating expenses3Adjusted increase in operating expenses3For the year ended December 31, 20195Corporating expenses3Adjusted increase in operating expenses3For the year ended December 31, 20195Adjusted increase in operating expenses5Torme Corporating expenses5Adjusted increase in operating expenses5Statistical increase in operating expenses5Adjusted increase in operating expenses5Net allog and expensions5Net allog and expen	For the year ended December 31, 2019					
Impact of exchange rule examples 1.122 \$ 22.00 Por the year existed December 31, 2018 28.00 3 20.735 Objecting income as reported \$ 27.00 8 Adjusted portenting income for the year ended December 31, 2019 \$ 20.735 Reconciliation between GAAP and Non-GAAP comparing expense: 5 58.670 For the year ended December 31, 2019 \$ 58.631 Operating expense is reported \$ 58.770 Adjusted operating expense is reported \$ 58.770 Adjusted operating expense for the year ended December 31, 2019 \$ 58.5327 Operating expense is reported \$ 53.201 Adjusted operating expense for the year ended December 31, 2019 \$ 53.201 Adjusted operating expense for the year ended December 31, 2019 \$ 53.201 Port hey are ended December 31, 2019 \$ 53.201 Adjusted operating expense for the year ended December 31, 2019 \$ 53.201 Nati gets as reported \$ 117.222 \$ Port hey are ended December 31, 2019 \$ \$ 54.433 Nati gets as reported \$ \$ 23.300 Adjusted projected net sales increase for the year ended December 31, 2018 \$ \$		\$,			
Adjusted premium income S 22,444 For the year ended December 31,2018 28,269 28,269 20,735 3 20,735 Adjusted increase in operating income S (7,274) S 20,735 8 Adjusted increase in operating income S (7,274) S 20,735 8 Adjusted increase in operating income S (7,274) S 20,735 8 Comparing operating income S (7,274) S 50,670 8 Impact of apprents as reported S (7,474) S 58,531 Port my year model December 31, 2018 S (159) S 58,531 Operating operating operating expenses S (7,474) S 53,204 Adjusted increase in operating expenses for the year ended December 31, 2019 S 53,204 45,730 Reconciliation between OAAP projectied asies provit: For the year ended December 31, 2019 S 122,112 Impact of apprents as reported S 122,112 S 122,715 Port my year ended December 31, 2019 S 122,715 S 122,715 Net impact of acquisition exclusitions S 122,715 S 122,715 Port my year ended December 31, 2018						
Operating income as reported 22.029 Impact of quistion ancipation and diversiture \$ (7.472) Adjusted increase in operating income \$ 1,700 Reconciliation between GAAP and Non-GAAP generating segments: \$ \$5.8,670 For the year ended December 31, 2019 \$ \$86,831 Operating promes as reported \$ \$8,670 Impact of restructuring drags \$ \$8,670 Impact of genes as reported \$ \$2,627 Internet of the year ended December 31, 2019 \$ \$122,112 Net sales per gularize \$ \$ \$2,300 Internet of compacting per			1,122	\$	22,444	
Impact of gain on acquisition and diversitive S (7,474) Adjusted increase in operating income for the year ended December 31, 2019 3 1,709 Responding to prevent as insported \$ 9,8670 Operating expense as reported \$ 9,8670 Impact of particip expense as reported \$ 9,8670 Adjusted operating expense as reported \$ 7,474 \$ Adjusted operating expense as reported \$ 7,474 \$ \$ Adjusted operating expense as reported \$ 7,474 \$ \$ \$ Adjusted operating expense as reported \$ 7,474 \$ \$ \$ Adjusted operating expense as reported \$ 120,112 \$ \$ \$ Impact of acquisition schulding currency \$ 120,112 \$ \$ \$ \$ Adjusted projected net sales \$ 117,232 \$ \$ \$ \$ Adjusted increase for the year ended December 31, 2019 \$ \$ 23,865 \$ \$ Net tanget of a						
Adjusted operating income \$ 20.735 Adjusted increase in operating income for the year ended December 31, 2019 3 1,709 95, Reconciliation between GAAP and Non-GAAP operating expense: 5 58,670 (139) 5 68,631 Port the year ended December 31, 2019 \$ 5 58,670 (139) 5 68,631 Port the year ended December 31, 2018 \$ 5,7471 \$ 5,3272 10% Reconciliation between GAAP and Non-GAAP properties alsel growth: \$ 129,112 10% 10% Reconciliation between GAAP and Non-GAAP properties alsel growth: \$ 129,112 10% For the year ended December 31, 2020 \$ 117,232 10% Net sates per guidance \$ 117,232 \$ 117,232 Adjusted increase in operating expenses for the year ended December 31, 2020 \$ 117,232 \$ Net sates a sequented \$ 129,112 \$ 117,232 Adjusted int tables \$ 122,715 \$ 5 For the year ended December 31, 2019 \$ 117,232 \$ \$ Net sates as expended \$ 23,855 \$ 5 For the year ended December 31, 2019 \$ \$ 23,855		¢				
Adjusted increase in operating income for the year ended December 31, 2019 \$ 1,709 8% Reconciliation between GAAP and Non-GAAP operating expense: For the year ended December 31, 2019 \$ 5,8070 (139) 5,8070 (172) 5,8080<td></td><td>φ</td><td>(7,474)</td><td>\$</td><td>20,735</td><td></td>		φ	(7,474)	\$	20,735	
Reconciliation between GAAP and Non-GAAP operating expense: For the year ended December 31, 2019 \$ 5 58,670 (139) 5 59,271 5 53,204 45,733 53,204 45,733 53,227 (0%) Reconciliation between GAAP and Non-GAAP projected sales growth: For the year ended December 31, 2019 117,232 5,483 548 55% Reconciliation between GAAP and Non-GAAP XanoSure sales growth: For the year ended December 31, 2018 Adjusted Anoburc 413, 2018	, , , ,					
For the year ended December 31, 2019 \$ 5 56,670 Operating express as reported 1(39) \$ 56,670 Impact of restructing charge 5 66,670 53,272 Por the year ended December 31, 2019 \$ 5,327 10% Reconclusion between GAAP and Non-GAAP projected sales growth: \$ 122,112 \$ 10% Reconclusion between GAAP and Non-GAAP projected sales growth: \$ 122,715 \$ 122,715 For the year ended December 31, 2019 \$ \$ 122,715 \$ 122,715 Net sales per guidance \$ 117,232 \$ \$ 122,715 For the year ended December 31, 2019 \$ \$ 122,715 \$ \$ 122,715 Reconclusion between GAAP and Non-GAAP ZenoSure sales growth: \$ 122,715 \$ \$ 122,715 \$ \$ 122,715 \$ \$ 122,715 \$ \$ 122,715 \$ \$ 122,715 \$ \$ \$ \$ 122,715 \$ \$ 122,715 \$ \$ \$ \$ \$ \$ \$ </td <td>Adjusted increase in operating income for the year ended December 31, 2019</td> <td></td> <td></td> <td>\$</td> <td>1,709</td> <td>8%</td>	Adjusted increase in operating income for the year ended December 31, 2019			\$	1,709	8%
Impact of restructuring charge (139) S 58,531 For the year anded December 31, 2019 0 perating expense as reported 5 7,474 S 53,204 Adjusted increase in operating expense for the year anded December 31, 2019 S 5,327 10% Reconciliation between GAAP and Non-CAAP projected sales growth: For the year anded December 31, 2029 S 129,112 10% Net states are product on the seles increase for the year anded December 31, 2019 S 122,715 S 122,715 For the year anded December 31, 2019 Net states are product on the sales increase for the year anded December 31, 2020 S 122,715 Net states as reported S 117,232 S 117,232 Adjusted projected net sales increase for the year ended December 31, 2020 S 23,855 Net states as reported S 23,855 5% Adjusted projected net sales increase for the year ended December 31, 2019 S 23,855 5% For the year anded December 31, 2019 S 23,855 5% 23,855 Particle year ended December 31, 2019 S 1,468 3 35,22 2% Adjusted sales for the year ended December 31, 20	For the year ended December 31, 2019					
Adjusted operating expense s 58.531 For the year ended December 31, 2018 \$ 45,730 7,474 \$ \$ 53,204 Adjusted increase in operating expense \$ 7,474 \$ \$ 53,204 Adjusted increase in operating expense \$ 120,112 \$ 5,327 10% Reconciliation between GAAP and Non-GAAP projected sales growth: \$ 122,112 \$ \$ 122,715 For the year ended December 31, 2019 \$ \$ 122,715 \$ 122,715 Net impact of acyulations excluding currency \$ \$ 117,232 \$ \$ Adjusted projected net sales \$ 117,232 \$ \$ 5% Reconciliation between GAAP and Non-GAAP XenoSure sales growth: \$ 23,865 \$ \$ For the year ended December 31, 2019 \$ \$ 23,865 \$ \$ NenoSure sales as reported \$ \$ 23,865 \$ \$ \$ Adjusted zales for the year ended December 31, 2019 \$ \$ \$ \$ \$ NenoSure sales as reported \$ \$ 23,865 \$ \$ \$ For the year ended December 31, 2019 \$ \$ \$ </td <td></td> <td>\$</td> <td></td> <td></td> <td></td> <td></td>		\$				
Operating expense as reported Impact of gains on acquisitions Adjusted operating expense 45,730 7,747 \$ 53,204 Adjusted increase in operating expense Adjusted increase in operating expense for the year ended December 31, 2019 \$ 5,327 10% Reconciliation between GAAP and Non-GAAP projected sales growth: For the year ended December 31, 2020 \$ 129,112 365 Net inspact of acquisitions excluding currency Adjusted projected net sales \$ 117,232 \$ 122,715 For the year ended December 31, 2019 \$ 117,232 \$ 117,232 \$ 5 122,715 Reconciliation between GAAP and Non-GAAP XenoSure sales growth: For the year ended December 31, 2019 \$ 117,232 \$ 5 5% NenoSure sales as reported Adjusted projected net sales increase for the year ended December 31, 2019 \$ 23,385 23,855 For the year ended December 31, 2019 \$ 23,385 \$ 23,223 2½ Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 \$ 1,608 \$ 23,385 \$ 23,385 \$ 23,223 2½ Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 \$			(139)	\$	58,531	
Operating expense as reported Impact of gains on acquisitions Adjusted operating expense 45,730 7,747 \$ 53,204 Adjusted increase in operating expense Adjusted increase in operating expense for the year ended December 31, 2019 \$ 5,327 10% Reconciliation between GAAP and Non-GAAP projected sales growth: For the year ended December 31, 2020 \$ 129,112 365 Net inspact of acquisitions excluding currency Adjusted projected net sales \$ 117,232 \$ 122,715 For the year ended December 31, 2019 \$ 117,232 \$ 117,232 \$ 5 122,715 Reconciliation between GAAP and Non-GAAP XenoSure sales growth: For the year ended December 31, 2019 \$ 117,232 \$ 5 5% NenoSure sales as reported Adjusted projected net sales increase for the year ended December 31, 2019 \$ 23,385 23,855 For the year ended December 31, 2019 \$ 23,385 \$ 23,223 2½ Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 \$ 1,608 \$ 23,385 \$ 23,385 \$ 23,223 2½ Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 \$	For the year ended December 31, 2018					
Adjusted operating expense \$ 53.204 Adjusted increase in operating expense for the year ended December 31, 2019 \$ 5.327 10% Reconciliation between GAAP and Non-GAAP projected sales growth: For the year ended December 31, 2020 \$ 5.327 10% Non-GAAP and Non-GAAP projected reliables \$ 129,112 5 10% Impact of coursely exchange rate fluctuations \$ 129,112 5 122,715 For the year ended December 31, 2019 \$ 117,232 \$ 127,715 Reconciliation between GAAP and Non-GAAP XenoSure sales growth: For the year ended December 31, 2019 \$ 117,232 \$ 5% Reconciliation between GAAP and Non-GAAP XenoSure sales growth: For the year ended December 31, 2019 \$ 23,865 5% Reconciliation between GAAP and Non-GAAP XenoSure sales growth: For the year ended December 31, 2019 \$ 23,865 23,855 For the year ended December 31, 2019 \$ 23,320 23,855 23,855 For the year ended December 31, 2018 \$ 1,668 1 34,232 24,252 Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2018 \$ 1,608 \$ 1,			45,730			
Adjusted increase in operating expense for the year ended December 31, 2019 \$ 5, 327 10% Reconciliation between GAAP and Non-GAAP projected sales growth: For the year ended December 31, 2020 \$ 129, 112 365 Net sales per guidance \$ 129, 123 365 365 For the year ended December 31, 2019 \$ 117, 232 \$ 122, 715 Adjusted projected net sales		\$	7,474			
Reconciliation between GAP and Non-GAAP projected sales growth: S 129,112 Not sales program \$ 129,112 Net subscription 365 Net subscription \$ Net subscription \$ Adjusted projected net sales \$ For the year ended December 31, 2019 \$ Net subscription \$ Adjusted projected net sales \$ Adjusted projected net sales \$ Adjusted projected net sales \$ Reconciliation between GAAP and Non-GAAP XenoSure sales growth: \$ For the year ended December 31, 2019 \$ XenoSure sales as reported \$ Adjusted net sales \$ Adjusted Soft December 31, 2019 \$ For the year ended December 31, 2019 \$ For the year ended December 31, 2019 \$ Reconciliation between GAAP and Non-GAAP China sales growth: \$ For the year ended December 31, 2019 \$ China sales as reported \$ Adjusted Viourney secting rate fluctuations \$ Adjusted Account 31, 2019 \$ China sales as reported \$ Adjusted China sales increase for the year ended December 31, 2018 Reconciliation between GAAP and Non-GAAP Value China sales	Adjusted operating expense			\$	53,204	
For the year ended December 31, 2020 \$ 129, 112 Impact of currency exchange rate fluctuations 365 Not singer of acquisitions excluding currency 366 Adjusted projected net sales (6,722) For the year ended December 31, 2019 \$ 117,232 Adjusted projected net sales \$ 23,860 Adjusted projected net sales \$ 23,860 Reconciliation between GAAP and Non-GAAP XenoSure sales growth: \$ 23,860 For the year ended December 31, 2019 \$ 23,860 XenoSure sales as reported \$ 23,860 Impact of currency exchange rate fluctuations 495 Adjusted projected net sales increase for the year ended December 31, 2019 \$ 23,860 Kenonciliation between GAAP and Non-GAAP XenoSure sales growth: \$ 23,865 For the year ended December 31, 2019 \$ 23,855 Reconciliation between GAAP and Non-GAAP China sales growth: \$ 532 2% For the year ended December 31, 2018 \$ 117,232 \$ 532 2% Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 \$ 1,508 \$ 1,508 For the year ended December 31, 2019 \$ 1,468 \$ 1,508 \$ 347 30%	Adjusted increase in operating expense for the year ended December 31, 2019)		\$	5,327	10%
Net sales per guidance \$ 122,112 Impact of currency exchange rate fluctuations 365 Net impact of acquisitions excluding currency 365 Adjusted projected net sales \$ For the year ended December 31, 2019 \$ Net sales as reported \$ Adjusted not ent sales \$ Adjusted not ent sales \$ Adjusted not ent sales \$ Adjusted projected net sales \$ Net sales as reported \$ XenoSure sales as reported \$ Adjusted XenoGaure sales increase for the year ended December 31, 2018 \$ China sales as reported \$ Impact of currency exchange rate fluctuations \$ Adjusted XenoGaure sales increase for the year ended December 31, 2019 \$ For the year ended December 31, 2019 \$ China sales as reported \$ Impact of currency exchange rate fluc						
Impact of currency exchange rate fluctuations 385 Net impact of acquisitions excluding currency (6,762) Adjusted projected net sales \$ 117,232 For the year ended December 31, 2019 \$ 117,232 Adjusted projected net sales increase for the year ended December 31, 2020 \$ 5,483 5% Reconciliation between GAAP and Non-GAAP XenoSure sales growth: \$ 23,360 \$ 23,360 Impact of currency exchange rate fluctuations 495 \$ 23,323 Adjusted projected net sales increase for the year ended December 31, 2019 \$ 23,360 \$ 23,355 For the year ended December 31, 2019 \$ 23,365 \$ 23,355 Port the year ended December 31, 2018 \$ 5,322 2% Adjusted XenoSure sales increase for the year ended December 31, 2018 \$ 5,322 2% Reconciliation between GAAP and Non-GAAP China sales growth: \$ 1,468 \$ 1,468 Impact of acquisitions \$ 1,468 \$ 1,508 \$ 3,2019 China sales as reported \$ 1,608 \$ 1,608 \$ 3,2019 Reconciliation between GAAP and Non-GAAP China sales growth: \$ 1,608 \$ 3,2019 \$ 3,2019 For the year ended December 31, 2019 \$ 1,608 \$ 1,508 \$ 3,2019		\$	129,112			
Adjusted projected net sales \$ 122,715 For the year ended December 31, 2019 \$ 117,232 Adjusted projected net sales increase for the year ended December 31, 2020 \$ 5,483 5% Reconciliation between GAAP and Non-GAAP XenoSure sales growth: For the year ended December 31, 2019 \$ 23,360 \$ 23,323 For the year ended December 31, 2018 \$ 23,323 \$ 23,323 XenoSure sales as reported \$ 3,233 \$ 532 2% Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2018 \$ 23,323 \$ 23,323 Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 \$ 1,468 \$ 1,508 Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 \$ 1,468 \$ 1,508 Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 \$ 1,468 \$ 1,508 Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2019 \$ 1,468 \$ 1,508 Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2019 \$ 1,601 \$ 30% Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2018 \$ 22,072 \$ 347 30%						
For the year ended December 31, 2019 \$ 117,232 Adjusted net sales \$ 117,232 Adjusted net sales \$ 117,232 Adjusted net sales \$ 5,483 Peconciliation between GAAP and Non-GAAP XenoSure sales growth: \$ 23,360 For the year ended December 31, 2019 \$ 23,360 XenoSure sales as reported \$ 23,360 Adjusted atles increase for the year ended December 31, 2019 \$ 23,365 For the year ended December 31, 2019 \$ 23,360 Adjusted AenoSure sales increase for the year ended December 31, 2019 \$ 23,323 For the year ended December 31, 2019 \$ 5 For the year ended December 31, 2019 \$ 5 China sales are ported \$ 1,468 Impact of currency exchange rate fluctuations \$ 1,468 Impact of currency exchange rate fluctuations \$ 1,608 China sales as reported \$ 1,508 For the year ended December 31, 2019 \$ 1,508 For the year ended December 31, 2019 \$ 1,508 Reconciliation between GAAP and Non-GAAP Valvulutomes sales growth: \$ 1,161 For the year ended December 31, 2019 \$ 2,072 Net sales as reported \$ 2,072 Adjusted A			(6,762)			
Net sales as reported Adjusted net sales \$ 117,232 Adjusted projected net sales increase for the year ended December 31, 2020 \$ 5,483 5% Reconciliation between GAAP and Non-GAAP XenoSure sales growth: For the year ended December 31, 2019 \$ 23,360 495 XenoSure sales as reported Impact of currency exchange rate fluctuations Adjusted sales for the year ended December 31, 2018 \$ 23,360 532 23,855 For the year ended December 31, 2018 \$ 23,323 23,855 532 23,855 For the year ended December 31, 2018 \$ \$ 23,323 20% Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 \$ 1,468 \$ 1,508 For the year ended December 31, 2019 \$ 1,468 \$ 1,509 \$ 3,47 30% For the year ended December 31, 2019 \$ 1,468 \$ 1,509 \$ 2,1161 \$ 3,47 30% \$ Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2018 \$ 2,2072 1,161 \$ 3,47 30% \$ 2,1,130 \$ 2,1,130 <t< td=""><td>Adjusted projected net sales</td><td></td><td></td><td>\$</td><td>122,715</td><td></td></t<>	Adjusted projected net sales			\$	122,715	
Adjusted net sales \$ 117,232 Adjusted projected net sales increase for the year ended December 31, 2020 \$ \$ 5,483 5% Reconciliation between GAAP and Non-GAAP XenoSure sales growth: For the year ended December 31, 2019 \$ 23,360 117,232 XenoSure sales as reported \$ 23,360 495 \$ 23,855 For the year ended December 31, 2018 \$ 23,323 2% XenoSure sales as reported \$ \$ 23,323 2% Adjusted XenoSure sales increase for the year ended December 31, 2018 \$ 5 532 2% Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 \$ 1,468 1 1,508 Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 \$ 1,508 5 347 30% Por the year ended December 31, 2019 \$ 1,161 \$ 347 30% Por the year ended December 31, 2019 \$ 2,2072 \$ 1,161 \$ 347 30% Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2018 \$ 22,072 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
Adjusted projected net sales increase for the year ended December 31, 2020 \$ 5,483 5% Reconciliation between GAAP and Non-GAAP XenoSure sales growth: For the year ended December 31, 2019 \$ 23,360 YenoSure sales as reported 495 \$ 23,855 For the year ended December 31, 2019 \$ 23,855 For the year ended December 31, 2018 \$ 23,855 XenoSure sales increase for the year ended December 31, 2018 \$ 23,855 Reconciliation between GAAP and Non-GAAP China sales growth: \$ 5,322 2% For the year ended December 31, 2019 \$ 1,468 \$ 1,508 Reconciliation between GAAP and Non-GAAP China sales growth: \$ 1,468 \$ 347 30% For the year ended December 31, 2019 \$ 1,468 \$ 347 30% Reconciliation between GAAP and Non-GAAP Valvuotomes sales growth: \$ 1,508 \$ 347 30% For the year ended December 31, 2019 \$ 1,508 \$ 347 30% Reconciliation between GAAP and Non-GAAP Valvuotomes sales growth: \$ 22,072 \$ 347 30% For the year ended December 31, 2019 \$ 22,072 \$ 1,161 \$ 347 30% Reconciliation between GAAP and Non-GAAP Valvuotomes sales growth: \$ 22,072 \$ 1,13		\$	117,232	¢	447.000	
Reconciliation between GAAP and Non-GAAP XenoSure sales growth: \$ 23,360 For the year ended December 31, 2019 \$ 23,855 For the year ended December 31, 2018 \$ 23,855 Adjusted sales for the year ended December 31, 2019 \$ 23,825 For the year ended December 31, 2018 \$ 5322 XenoSure sales as reported \$ 5322 Adjusted XenoSure sales increase for the year ended December 31, 2018 \$ 532 Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 China sales as reported \$ 1,468 Impact of currency exchange rate fluctuations 40 Adjusted sales for the year ended December 31, 2019 \$ 1,508 For the year ended December 31, 2019 \$ 1,508 For the year ended December 31, 2019 \$ 1,508 Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: \$ 1,161 For the year ended December 31, 2018 \$ 22,072 China sales as reported \$ 22,072 Adjusted for unrency exchange rate fluctuations \$ 415 Net sales as reported \$ 22,072 Impact of currency exchange rate fluctuations \$ 415 Net sales as reported \$ 21,130 For	Adjusted net sales			\$	117,232	
For the year ended December 31, 2019 \$ 23,360 XenoSure sales as reported \$ 23,360 Adjusted sales for the year ended December 31, 2019 \$ 23,360 For the year ended December 31, 2018 \$ 23,323 XenoSure sales as reported \$ 532 Adjusted XenoSure sales increase for the year ended December 31, 2018 \$ 532 Reconciliation between GAAP and Non-GAAP China sales growth: \$ 1,468 For the year ended December 31, 2019 \$ 1,508 China sales as reported \$ 1,508 Adjusted Sales for the year ended December 31, 2019 \$ 1,508 For the year ended December 31, 2019 \$ 1,508 For the year ended December 31, 2019 \$ 1,508 For the year ended December 31, 2019 \$ 1,508 Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: \$ 1,508 For the year ended December 31, 2018 \$ 1,508 Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: \$ 22,072 For the year ended December 31, 2019 \$ 22,072 Net sales as reported \$ 21,130 Adjusted net sales \$ 21,130 For the year ended December 31, 2018 \$ 20,483 Net sales as reported \$ 20,483 </td <td>Adjusted projected net sales increase for the year ended December 31, 2020</td> <td></td> <td></td> <td>\$</td> <td>5,483</td> <td>5%</td>	Adjusted projected net sales increase for the year ended December 31, 2020			\$	5,483	5%
For the year ended December 31, 2019 \$ 23,360 XenoSure sales as reported \$ 23,360 Adjusted sales for the year ended December 31, 2019 \$ 23,360 For the year ended December 31, 2018 \$ 23,323 XenoSure sales as reported \$ 532 Adjusted XenoSure sales increase for the year ended December 31, 2018 \$ 532 Reconciliation between GAAP and Non-GAAP China sales growth: \$ 1,468 For the year ended December 31, 2019 \$ 1,508 China sales as reported \$ 1,508 Adjusted Sales for the year ended December 31, 2019 \$ 1,508 For the year ended December 31, 2019 \$ 1,508 For the year ended December 31, 2019 \$ 1,508 For the year ended December 31, 2019 \$ 1,508 Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: \$ 1,508 For the year ended December 31, 2018 \$ 1,508 Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: \$ 22,072 For the year ended December 31, 2019 \$ 22,072 Net sales as reported \$ 21,130 Adjusted net sales \$ 21,130 For the year ended December 31, 2018 \$ 20,483 Net sales as reported \$ 20,483 </td <td>Reconciliation between GAAP and Non-GAAP XenoSure sales growth:</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Reconciliation between GAAP and Non-GAAP XenoSure sales growth:					
Impact of currency exchange rate fluctuations 495 Adjusted sales for the year ended December 31, 2019 \$ 23,855 For the year ended December 31, 2018 \$ 23,323 XenoSure sales as reported \$ 23,323 Adjusted XenoSure sales increase for the year ended December 31, 2018 \$ 532 Reconciliation between GAAP and Non-GAAP China sales growth: \$ 1,468 For the year ended December 31, 2019 \$ 1,508 China sales as reported \$ 1,508 Adjusted China sales increase for the year ended December 31, 2019 \$ 1,508 For the year ended December 31, 2018 \$ 347 China sales as reported \$ 22,072 Adjusted China sales increase for the year ended December 31, 2018 \$ 22,072 For the year ended December 31, 2019 \$ 347 Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: \$ 22,072 For the year ended December 31, 2019 \$ 22,072 Net sales as reported \$ 22,072 Adjusted of acquisitions excluding currency \$ 22,072 Impact of currency exchange rate fluctuations \$ 22,072 Net impact of acquisitions excluding currency \$ 22,072 Adjusted net sales \$ 21,130 For t						
Adjusted sales for the year ended December 31, 2019 \$ 23,855 For the year ended December 31, 2018 \$ 23,323 XenoSure sales as reported \$ 23,323 Adjusted XenoSure sales increase for the year ended December 31, 2018 \$ 532 Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 China sales as reported \$ 1,468 Impact of currency exchange rate fluctuations 40 Adjusted Sales for the year ended December 31, 2019 \$ 1,508 For the year ended December 31, 2018 \$ 347 China sales as reported \$ 22,072 Adjusted China sales increase for the year ended December 31, 2018 \$ 22,072 Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2018 For the year ended December 31, 2019 \$ 1,161 Net sales as reported \$ 22,072 Impact of currency exchange rate fluctuations \$ 11,337 Net sales as reported \$ 21,130 For the year ended December 31, 2018 \$ 21,130 For the year ended December 31, 2018 \$ 21,130 Net sales as reported \$ 21,130 For the year ended December 31, 2018 \$ 20,483		\$				
For the year ended December 31, 2018 \$ 23,323 Adjusted XenoSure sales increase for the year ended December 31, 2018 \$ 532 Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 For the year ended December 31, 2019 \$ 1,468 Impact of currency exchange rate fluctuations 40 Adjusted Sales for the year ended December 31, 2019 \$ 1,508 For the year ended December 31, 2019 \$ 1,161 China sales as reported \$ 1,161 Adjusted China sales increase for the year ended December 31, 2018 \$ 347 Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2019 For the year ended December 31, 2018 \$ 1,161 Adjusted China sales increase for the year ended December 31, 2018 \$ 22,072 Impact of currency exchange rate fluctuations \$ 415 Net sales as reported \$ 22,072 Impact of acquisitions excluding currency \$ 1,1377 Adjusted net sales \$ 20,483 For the year ended December 31, 2018 \$ 20,483			495	^	00.055	
XenoSure sales as reported \$ 23,323 Adjusted XenoSure sales increase for the year ended December 31, 2018 \$ 532 2% Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 \$ 1,468 20 China sales as reported Impact of currency exchange rate fluctuations Adjusted sales for the year ended December 31, 2019 \$ 1,508 \$ 1,508 For the year ended December 31, 2018 \$ 1,161 \$ 347 30% Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2018 \$ 22,072 \$ 347 30% Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2019 \$ 22,072 \$ 347 30% Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2019 \$ 22,072 \$ 347 30% Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2019 \$ 22,072 \$ 347 30% Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2019 \$ 22,072 \$ 1,130 For the year ended December 31, 2018 \$ 22,072 \$ 21,130 \$ 21,130 For the year ended December 31, 2018 \$ 20,483 \$ 20,483 \$ 20,483 \$ 20,483	Adjusted sales for the year ended December 31, 2019			\$	23,855	
Adjusted XenoSure sales increase for the year ended December 31, 2018 \$ 532 2% Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 \$ 1,468 40 China sales as reported \$ 1,468 40 \$ 1,508 For the year ended December 31, 2019 \$ 1,508 \$ 1,161 For the year ended December 31, 2018 \$ 1,161 30% China sales as reported \$ 1,161 \$ 347 30% Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2018 \$ 22,072 \$ 347 30% Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2019 \$ 22,072 \$ 3147 30% Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2019 \$ 22,072 \$ 3147 30% Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2019 \$ 22,072 \$ 3147 30% Net sales as reported Adjusted net sales \$ 22,072 \$ 31,130 \$ 21,130 For the year ended December 31, 2018 Net sales as reported Adjusted net sales \$ 20,483 \$ 20,483 \$ 20,483 \$ 20,483 \$ 20,483 \$ 20,483				\$	23 323	
Reconciliation between GAAP and Non-GAAP China sales growth: For the year ended December 31, 2019 China sales as reported Impact of currency exchange rate fluctuations Adjusted sales for the year ended December 31, 2019 For the year ended December 31, 2018 China sales as reported Adjusted China sales increase for the year ended December 31, 2018 Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2018 Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2019 Net sales as reported Adjusted China sales increase for the year ended December 31, 2018 Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2019 Net sales as reported Impact of currency exchange rate fluctuations Net sales as reported Net sales as reported S 22,072 Impact of currency exchange rate fluctuations Net sales as reported \$ Net sales as reported \$ Adjusted net sales \$ S 20,483						2%
For the year ended December 31, 2019 \$ 1,468 Impact of currency exchange rate fluctuations 40 Adjusted sales for the year ended December 31, 2019 \$ 1,508 For the year ended December 31, 2018 \$ 1,161 China sales as reported \$ 1,161 Adjusted China sales increase for the year ended December 31, 2018 \$ 1,161 Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: \$ 22,072 For the year ended December 31, 2019 \$ 22,072 Net sales as reported \$ 21,130 For the year ended December 31, 2018 \$ 21,130 For the year ended December 31, 2018 \$ 20,483 Net sales as reported \$ 20,483	Aujusted Actionale sales inclease for the year clued December 31, 2010			φ	552	2.76
China sales as reported Impact of currency exchange rate fluctuations Adjusted sales for the year ended December 31, 2019\$ 1,468 40For the year ended December 31, 2018 China sales as reported Adjusted China sales increase for the year ended December 31, 2018\$ 1,508Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2019\$ 22,072 (1,357)Net sales as reported Impact of currency exchange rate fluctuations Net impact of acquisitions excluding currency Adjusted net sales\$ 22,072 (1,357)For the year ended December 31, 2018\$ 22,072 (1,357)For the year ended December 31, 2018 Net sales as reported Adjusted net sales\$ 20,483For the year ended December 31, 2018 Net sales as reported Adjusted net sales\$ 20,483						
Adjusted sales for the year ended December 31, 2019 \$ 1,508 For the year ended December 31, 2018 \$ 1,161 China sales as reported \$ 1,161 Adjusted China sales increase for the year ended December 31, 2018 \$ 347 Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: \$ 22,072 For the year ended December 31, 2019 \$ 22,072 Net sales as reported \$ 11,161 Impact of currency exchange rate fluctuations \$ 1,161 Net impact of acquisitions excluding currency \$ 1,130 For the year ended December 31, 2018 \$ 21,130 For the year ended December 31, 2018 \$ 20,483 Net sales as reported \$ 20,483		\$	1,468			
For the year ended December 31, 2018 \$ 1,161 China sales as reported \$ 347 Adjusted China sales increase for the year ended December 31, 2018 \$ 347 Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: \$ 22,072 For the year ended December 31, 2019 \$ 22,072 Net sales as reported \$ 115 Impact of currency exchange rate fluctuations \$ 415 Net impact of acquisitions excluding currency \$ 21,130 For the year ended December 31, 2018 \$ 20,483 Net sales as reported \$ 20,483			40			
China sales as reported\$1,161Adjusted China sales increase for the year ended December 31, 2018\$34730%Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2019 Net sales as reported\$22,072Impact of currency exchange rate fluctuations Net impact of acquisitions excluding currency Adjusted net sales\$22,072For the year ended December 31, 2018 Net sales as reported\$21,130For the year ended December 31, 2018 Net sales as reported Adjusted net sales\$20,483Set 20,483\$20,483				\$	1,508	
Reconciliation between GAAP and Non-GAAP Valvulotomes sales growth: For the year ended December 31, 2019 Net sales as reported \$ 22,072 Impact of currency exchange rate fluctuations 415 Net impact of acquisitions excluding currency (1,357) Adjusted net sales \$ 20,483 For the year ended December 31, 2018 \$ 20,483 Net sales as reported \$ 20,483				\$	1,161	
For the year ended December 31, 2019 \$ 22,072 Net sales as reported \$ 22,072 Impact of currency exchange rate fluctuations 415 Net impact of acquisitions excluding currency (1,357) Adjusted net sales \$ 21,130 For the year ended December 31, 2018 \$ 20,483 Net sales as reported \$ 20,483 Adjusted net sales \$ 20,483	Adjusted China sales increase for the year ended December 31, 2018			\$	347	30%
Net sales as reported \$ 22,072 Impact of currency exchange rate fluctuations 415 Net impact of acquisitions excluding currency (1,357) Adjusted net sales \$ 21,130 For the year ended December 31, 2018 \$ 20,483 Net sales as reported \$ 20,483 Adjusted net sales \$ 20,483						
Impact of currency exchange rate fluctuations 415 Net impact of acquisitions excluding currency (1,357) Adjusted net sales \$ 21,130 For the year ended December 31, 2018 \$ 20,483 Net sales as reported \$ 20,483 Adjusted net sales \$ 20,483		\$	22,072			
Adjusted net sales \$ 21,130 For the year ended December 31, 2018 \$ 20,483 Net sales as reported \$ 20,483 Adjusted net sales \$ 20,483	•		415			
For the year ended December 31, 2018 Net sales as reported \$ 20,483 Adjusted net sales \$ 20,483			(1,357)			
Net sales as reported \$ 20,483 Adjusted net sales \$ 20,483	Adjusted net sales			\$	21,130	
Adjusted net sales <u>\$ 20,483</u>						
		\$	20,483	¢	20 402	
Adjusted net Valvulotomes sales increase for the year ended December 31, 2019 \$ 647 3%					·	
	Adjusted net Valvulotomes sales increase for the year ended December 31, 20	19		\$	647	3%

	For the three months ended				For the year ended			
	December 31, 2019		December 31, 2018		December 31, 2019		December 31, 2018	
Reconciliation between GAAP and Non-GAAP EBITDA			-					
Net income as reported	\$	4,613	\$	6,025	\$	17,934	\$	22,943
Interest (income) expense, net		(123)		(177)		(698)		(629)
Amortization and depreciation expense		1,430		1,216		5,405		4,324
Provision for income taxes		575		1,226		3,745		5,501
EBITDA	\$	6,495	\$	8,290	\$	26,386	\$	32,139